Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Analysis of Fcg Receptor haplotypes in rheumatoid arthritis

People with a specific combination of variants of two genes, encoding two different receptors for the antibody Fc gamma, are three times more likely to develop rheumatoid arthritis than individuals with different variant combinations.

28 Nov 2005

Researchers identify genes affected by Methotrexate (MTX)

A Queen's University study of fruit flies that may revolutionize the way birth defects are studied has identified the genes affected by a widely-prescribed drug known to cause birth defects.

26 Nov 2005

Warnings on popular asthma drug could damage drug giant

The U.S. Food and Drug Administration (FDA) is recommending new restrictions on the asthma drug Advair.

21 Nov 2005

Valproic acid (Depakote) may help treat lupus

A common anti-seizure drug may be effective against certain conditions associated with lupus, according to animal research at Wake Forest University School of Medicine.

20 Nov 2005

Lack of selenium increases risk of knee osteoarthritis

University of North Carolina at Chapel Hill Thurston Arthritis Center medical scientists and colleagues conducted the research. It focused on the knees of 940 participants enrolled in the Johnston County (N.C.) Osteoarthritis Project, a continuing, federally supported investigation of osteoarthritis that began 15 years ago and is headquartered at UNC.

20 Nov 2005

First nationwide study of pregnancy outcomes in women with rheumatic disease

The first nationwide study of pregnancy outcomes in women with rheumatic disease confirms that they experience greater pregnancy risks and longer hospital stays than the average pregnant woman.

20 Nov 2005

Trichostatin A may fight lupus and atherosclerosis simultaneously

People with lupus are prone to premature accelerated atherosclerosis. Now scientists at Wake Forest University School of Medicine think they have a way to prevent or decrease this atherosclerosis and prevent heart attacks.

16 Nov 2005

Cannabis-based medicine given go-ahead to treat MS patients

Sufferers in the UK from multiple sclerosis and possibly rheumatoid arthritis, will welcome the news that they will soon be able to obtain an unlicensed, cannabis-based medicine on prescription to treat their illness.

16 Nov 2005

It's true! study confirms that Glucosamine and Chondroitin relieve arthritis pain

The millions of Osteoarthritis sufferers in the world will welcome the good news that a new study has confirmed that the dietary supplements glucosamine and chondroitin provide pain relief.

15 Nov 2005

Mayo Clinic provides new strategy for designing better treatments for juvenile dermatomyositis

Mayo Clinic researchers, working with colleagues at the University of Minnesota and University of Pittsburgh, are the first to describe a new role for a specialized cell of the immune system in children suffering from a rare muscle-damaging disease known as juvenile dermatomyositis (JDM).

14 Nov 2005

Taking either COX-2 inhibitors or NSAIDs after a heart attack increases the risk of death

In recent years, evidence has shown that patients treated with selective cyclo-oxygenase-2 (COX-2) inhibitors are at increased risk of heart attack and death. COX-2 inhibitors are used primarily to treat pain and arthritis in patients at risk of gastrointestinal bleeding.

13 Nov 2005

Fc gamma receptor gene variants associated with rheumatoid arthritis

10 Nov 2005

Cannabis drug provides relief from rheumatoid arthritis

According to new research, a cannabis-based drug works as a painkiller and may also slow disease progression, in rheumatoid arthritis patients.

10 Nov 2005

First study to use a cannabis-based medicine for treating rheumatoid arthritis

The first study to use a cannabis-based medicine (CBM) for treating rheumatoid arthritis has found that it has a significant effect on easing pain and on suppressing the disease.

9 Nov 2005

Introgen's INGN 241 combined with Celebrex kills breast cancer cells

Introgen Therapeutics, Inc. today reported the publication of preclinical data demonstrating that INGN 241 works synergistically with celecoxib (Celebrex) marketed by Pfizer to inhibit the growth and increase apoptosis (cell death) of breast cancer cells.

8 Nov 2005